Conditional recommendation in favor of surveillance for nondysplastic BE, against surveillance for columnar-lined esophagus <1 cm<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
FRIDAY, Oct. 24, 2025 (HealthDay News) — Recommendations have been developed for surveillance of Barrett esophagus (BE), according to a report published in the November issue of Gastroenterology<\/em>.<\/p>\n Sachin Wani, M.D., from the University of Colorado Anschutz Medical Campus in Aurora, and colleagues developed guidelines to inform clinicians and patients by providing evidence-based practice recommendations for surveillance in patients with BE. Clinical questions and outcomes were prioritized according to their importance for clinicians and patients.<\/p>\n The panel agreed on eight recommendations. Based on the available evidence, for patients with nondysplastic BE, a conditional recommendation was made in favor of surveillance. A conditional recommendation against endoscopic surveillance was made for patients with columnar-lined esophagus <1 cm. A strong recommendation was made in favor of a combination of high-definition white-light endoscopy and chromoendoscopy versus white-light endoscopy alone. No recommendations were made on the use of enhanced sampling techniques, including wide-area transepithelial sampling to enhance detection of neoplasia and biomarkers such as p53 and TissueCypher for predicting progression in BE. A conditional recommendation was provided for use of a daily proton pump inhibitor versus no therapy and compared with antireflux surgery for preventing progression in BE.<\/p>\n “What’s novel here is our move away from a one-size-fits-all approach,” Wani said in a statement. “We focus on risk stratification and doing endoscopy right — because quality drives earlier detection of neoplasia and better outcomes.”<\/p>\n Several authors disclosed ties to the biopharmaceutical industry.<\/p>\n